This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers   FY26 Q3 revenue: $9.02 billion 8.7% growth year over year   Cardiovascular revenue: $3.46 billion Nearly 14% growth year over year   Diabetes revenue: $796 million Nearly 15% growth year over year Medtronic said Tuesday that a surgeon completed the first U.S. procedure for its Hugo robotic surgery system, shortly after the company received ...

Group 1 - Masimo stock experienced a significant increase following reports of a potential acquisition [1] - The company is widely recognized for its prolonged patent dispute with Apple [1]

Group 1: Investment Strategy - Pale Fire Capital has heavily bet against Coinbase, Tesla, and Robinhood by purchasing put options during the fourth quarter, indicating a strategic shift in its portfolio towards healthcare stocks [1] - The firm initiated a new position in Baxter International, acquiring 2,074,016 shares valued at approximately $39.63 million, which represents 2.66% of its $1.49 billion reportable U.S. equity AUM as of December 31, 2025 [3] Group 2: Company Overview - Baxter International Inc. is a leading provider of essential healthcare products and services, with a broad product suite and global reach, addressing critical needs in patient care across acute hospital settings and home-based therapies [2] - The company operates a global business model focused on the development, manufacturing, and distribution of medical devices and pharmaceuticals to healthcare providers [3] Group 3: Financial Performance - Baxter International reported significant net losses in 2024 and 2025, but fourth-quarter sales from continuing operations rose by 8% on a reported basis and 3% on an operational basis, with international sales growing by 8% year over year on an operational basis [5]

Core Insights - TransMedics (TMDX) has received full and unconditional FDA Investigational Device Exemption (IDE) approval for its OCS ENHANCE Heart trial, allowing for full trial execution and patient enrollment [1][7] - This approval significantly de-risks the clinical roadmap for TransMedics and enhances confidence in its long-term growth potential, as successful trial execution could lead to broader clinical indications and increased utilization of the OCS platform [2][4] Company Overview - TransMedics currently has a market capitalization of $4.44 billion [6] - The OCS ENHANCE Heart trial is a two-part clinical program designed to redefine donor heart preservation, with an enrollment target of 650 patients [7][8] - The trial aims to compare the OCS Heart System with traditional cold storage methods, potentially generating a robust clinical dataset for heart transplantation [8][9] Market Trends - The global organ transplantation market was valued at approximately $18.59 billion in 2023 and is projected to grow to around $33.32 billion by 2032, with a compound annual growth rate (CAGR) of roughly 6.70% [10] - The growth in the organ transplantation market is driven by increasing chronic disease cases, advancements in immunosuppression therapies, and innovations in organ preservation technologies [11] Strategic Developments - In January, TransMedics announced a long-term lease for its new global headquarters and acquired adjacent land for an integrated campus, indicating its commitment to innovation and growth in organ transplant therapy [12]

Core Viewpoint - Si-Bone (SIBN) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, which could significantly influence its stock price based on actual results compared to estimates [1][2]. Financial Expectations - The upcoming earnings report is scheduled for February 23, and a better-than-expected performance could lead to a rise in stock price, while a miss could result in a decline [2]. - The consensus estimate indicates a quarterly loss of $0.13 per share, reflecting an 18.2% decrease year-over-year, with revenues projected at $56.3 million, representing a 14.9% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst assessments during this period [4]. - Si-Bone's Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [8][9]. - Si-Bone currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [11]. Historical Performance - In the last reported quarter, Si-Bone was expected to post a loss of $0.16 per share but achieved a loss of $0.11, resulting in a positive surprise of 31.25% [12]. - Over the past four quarters, Si-Bone has consistently beaten consensus EPS estimates [13]. Conclusion - While Si-Bone does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding this stock ahead of its earnings release [16].

Core Insights - Johnson & Johnson's (JNJ) MedTech segment, which includes products in orthopedics, surgery, cardiovascular, and vision markets, represents approximately 36% of the company's total revenues, achieving nearly $34 billion in sales in 2025 with a 5.4% operational growth supported by 15 major new product launches [1][10] MedTech Segment Performance - J&J is transitioning its MedTech portfolio towards high innovation and high growth markets, particularly in Cardiovascular, with sales in this segment increasing by 15.8% to $8.9 billion in 2025 due to acquisitions of Shockwave and Abiomed [2][10] - The MedTech business has shown improvement over the last three quarters, driven by the acquired cardiovascular businesses and growth in Surgical Vision and wound closure, resulting in a 4.3% organic sales increase in 2025 [3][10] Challenges and Future Outlook - The company faces challenges in China due to the volume-based procurement (VBP) program, which is impacting sales growth in some MedTech areas [4] - For 2026, J&J anticipates better growth in the MedTech business compared to 2025, driven by the adoption of new products across its portfolios, although it expects continued VBP impacts in China and potential tariff costs of around $500 million [5][10] Strategic Developments - J&J is considering separating its Orthopaedics franchise into a standalone company, DePuy Synthes, by mid-2027, which is expected to enhance growth and margins for its MedTech unit in the long term [6] Competitive Landscape - J&J's MedTech unit competes with major players in the medical device industry, including Medtronic, Abbott, Stryker, and Boston Scientific, each specializing in various medical technologies [7][8] Stock Performance and Valuation - J&J's stock has outperformed the industry over the past year, rising 55.9% compared to the industry's 21.3% increase [9] - The company's shares are currently trading at a price/earnings ratio of 20.90, which is higher than the industry average of 18.83 and above its five-year mean of 15.65 [12] Earnings Estimates - The Zacks Consensus Estimate for J&J's 2026 earnings has increased from $11.47 to $11.54, while the estimate for 2027 has risen from $12.25 to $12.40 over the past 30 days [14]

Core Insights - Hologic's $18.3 billion acquisition by Blackstone and TPG is nearing completion, marking the largest medical devices deal in two decades, with 99.8% of shareholders approving the proposal [1][2] - The acquisition price of $76 per share, plus a contingent value right (CVR) of up to $3, represents a 46% premium over the stock price before the deal was announced [2] - Hologic's recent quarterly results showed a 2.5% year-over-year revenue increase but missed analyst expectations, particularly in Breast Health sales [5][6] Acquisition Details - Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash, with a potential additional $3 per share based on future revenue goals [2] - The total purchase price could reach $79 per share, indicating a 46% premium compared to the last trading day before acquisition rumors [2] - The stock is currently trading close to the buyout price, suggesting limited upside potential for existing shareholders [3][7] Financial Performance - Hologic reported first-quarter revenues of $1,047.8 million, a 2.5% increase year-over-year, but fell short of analyst forecasts [5][6] - Breast Health product revenues decreased by 2.2%, attributed to lower sales of digital mammography systems and related products [7] - GYN Surgical revenues increased by 8.7%, driven by higher sales from the acquired Gynesonics business [9] Market Position and Valuation - Hologic's shares have gained 1.2% over the past three months, outperforming the industry, which declined by 7.7% [14] - The company is trading at a forward Price-to-Sales (P/S) ratio of 3.86, higher than its historical median of 3.49 and the sector average of 2.24 [16] - Compared to competitors, Hologic's valuation appears elevated, with GE HealthCare and Medtronic trading at lower P/S ratios [16] Regulatory Developments - Hologic's Aptima HPV Assay received FDA approval for primary screening, expanding its cervical cancer screening offerings [12] - The approval follows extensive real-world studies involving over 650,000 women, enhancing the company's market position in cervical cancer diagnostics [12][13]

Core Insights - QuidelOrtho has entered a strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio, focusing on high-throughput and low-to-mid volume immunoassay analyzers [1] - The partnership aims to provide cost-efficient and scalable diagnostic solutions in selected international markets outside the US, enhancing QuidelOrtho's competitive edge [1][4] Product Expansion - The agreement will introduce over 25 new assays not currently available on QuidelOrtho's VITROS system, increasing the total number of assays on the new platforms to more than 70 [2] - This expansion is designed to meet broader tender requirements and cater to various laboratory environments, from low-volume solutions to larger settings [2][3] Market Impact - Laboratories will benefit from the expanded offering, which addresses menu gaps and enhances competitiveness in international tenders by providing more flexible system options [3] - QuidelOrtho's senior vice-president emphasized that the collaboration will accelerate the introduction of scalable testing solutions, aligning with the company's long-term innovation strategy in core growth markets [4]

Core Viewpoint - Edwards Lifesciences has eliminated its anti-copycat policy, leading to the closure of an EU antitrust investigation against the company [1]. Group 1: Company Actions - Edwards Lifesciences has withdrawn its Global Unilateral Pro-Innovation (Anti-Copycatting) Policy (UPIP), which was previously a point of contention with Indian rival Meril [1]. - The European Commission confirmed that the removal of the UPIP from the company's website indicates that the concerns regarding market power abuse have been addressed [1]. Group 2: Regulatory Context - The European Commission had conducted an investigation into Edwards Lifesciences after a complaint from Meril, which alleged that the company was abusing its market position [1]. - The Commission's investigation included a raid on one of Edwards Lifesciences' facilities in September 2023 [1]. - The closure of the investigation means that further action is not considered a priority at the EU level [1].

Core Viewpoint - Edwards Lifesciences Corporation is highlighted as a strong investment opportunity in the medical technology sector, particularly following its positive Q4 2025 earnings report which exceeded expectations [1][2]. Financial Performance - The company reported quarterly sales of $1.57 billion, reflecting an 11.6% increase year-over-year, surpassing both Stifel's estimate of $1.54 billion and the consensus estimate of $1.55 billion [1][2]. - Quarterly EPS was reported at $0.58, which was below the expected $0.62 due to higher-than-anticipated spending on sales, general, and administrative costs [3]. Revenue Drivers - Transcatheter aortic valve replacement (TAVR) sales, which constitute approximately 74% of the company's revenue, grew by 10.6% year-over-year, serving as the primary driver for the company's strong performance [2][4]. - Management indicated that TAVR growth is supported by favorable clinical results, new European guidelines, a competitor exiting the market, and increased adoption of the Sapien 3 Ultra Resilia valve [4]. Company Overview - Edwards Lifesciences specializes in developing and manufacturing medical technology focused on structural heart disease and critical care monitoring, with key products including transcatheter heart valves, surgical heart valves, and hemodynamic monitoring systems [5].